Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.
about
Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrataEpidemiology of invasive candidiasis: a persistent public health problemStimulation of chitin synthesis rescues Candida albicans from echinocandins.Acquisition of flucytosine, azole, and caspofungin resistance in Candida glabrata bloodstream isolates serially obtained from a hematopoietic stem cell transplant recipient.Population mobility, globalization, and antimicrobial drug resistance.Novel FKS mutations associated with echinocandin resistance in Candida species.High-temperature ethanol production using thermotolerant yeast newly isolated from Greater Mekong Subregion.Breakthrough invasive Candida glabrata in patients on micafungin: a novel FKS gene conversion correlated with sequential elevation of MIC.Target enzyme mutations confer differential echinocandin susceptibilities in Candida kefyrRecent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patientsAcquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.FKS2 mutations associated with decreased echinocandin susceptibility of Candida glabrata following anidulafungin therapy.Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance.Candida glabrata mutants demonstrating paradoxical reduced caspofungin susceptibility but increased micafungin susceptibilityEchinocandin susceptibility testing of Candida isolates collected during a 1-year period in Sweden.Elevated cell wall chitin in Candida albicans confers echinocandin resistance in vivo.Quick Detection of FKS1 Mutations Responsible for Clinical Echinocandin Resistance in Candida albicans.Candida spp. with acquired echinocandin resistance, France, 2004-2010.Mitochondrial sorting and assembly machinery subunit Sam37 in Candida albicans: insight into the roles of mitochondria in fitness, cell wall integrity, and virulenceDifferential in vivo activities of anidulafungin, caspofungin, and micafungin against Candida glabrata isolates with and without FKS resistance mutations.Epidemiology and antifungal resistance in invasive candidiasis.KRE5 Suppression Induces Cell Wall Stress and Alternative ER Stress Response Required for Maintaining Cell Wall Integrity in Candida glabrataThe presence of an FKS mutation rather than MIC is an independent risk factor for failure of echinocandin therapy among patients with invasive candidiasis due to Candida glabrata.CRS-MIS in Candida glabrata: sphingolipids modulate echinocandin-Fks interaction.Optimizing Echinocandin dosing and susceptibility breakpoint determination via in vivo pharmacodynamic evaluation against Candida glabrata with and without fks mutations.In search of the holy grail of antifungal therapyReduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment.Detection of caspofungin resistance in Candida spp. by Etest.Rapid emergence of echinocandin resistance during Candida kefyr fungemia treatment with caspofungin.The pharmacology and clinical use of caspofungin.Resistance to echinocandin-class antifungal drugs.Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrationsMutations in the fks1 gene in Candida albicans, C. tropicalis, and C. krusei correlate with elevated caspofungin MICs uncovered in AM3 medium using the method of the European Committee on Antibiotic Susceptibility Testing.Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection.Breakthrough Aspergillus fumigatus and Candida albicans double infection during caspofungin treatment: laboratory characteristics and implication for susceptibility testing.Antifungal drug resistance mechanisms.Recurrent episodes of Candidemia due to Candida glabrata, Candida tropicalis and Candida albicans with acquired echinocandin resistance.Novel antifungal drug discovery based on targeting pathways regulating the fungus-conserved Upc2 transcription factorCurrent perspectives on echinocandin class drugs.New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
P2860
Q28483785-D49F909D-A44D-4EB9-8D72-15B72D2A3809Q29616758-DF4E1062-4950-4C0A-B2EA-2C5FE9AD9283Q33326983-771031AF-92BC-4A67-894E-71284D2C843AQ33676430-DDD0BB3A-293E-47A5-AE58-27D38EC8A830Q33800616-883264D1-35C8-4F15-A592-BB2D398312CDQ33826330-97D5B593-440B-4755-A153-775C3542C3D8Q33875159-06372A01-16D6-4778-A8DF-AC2BA9461B89Q33900103-7D53867A-A21A-4B21-A7A1-17DEEE8DA0D8Q34057480-6AD0521D-932C-4C32-9F93-6A211EF7578FQ34529026-6BF505E3-179D-4E57-8F39-BF56499967B4Q34576400-9B948A04-1B1B-4EA1-9B89-0AADC2CE13D6Q34737334-7D135D52-7FB4-4AB2-9D41-FF8E3827F0FEQ35129428-77BAC2C6-19EE-41FB-B772-6B77E1B993FAQ35139474-EF88F32F-7A1F-430D-B414-0EDD56ED0326Q35140020-171FC669-48A6-483D-B298-D5761C48E6B2Q35666505-6F3FCD24-D4CA-4BF0-BEA0-268B0D090AB1Q35757564-A9F4438B-B042-4DBD-8B81-825549E4EFE1Q35845865-249B7121-A6E1-40E3-B9EB-9B69A2CF93B2Q35867270-162C66EB-166B-4184-9663-79E5E86C147DQ35941237-CFD8B9C1-D215-46E5-B3C5-54B0613684A2Q35959495-5B3EEBE9-0B84-4564-84D6-FBA19316D0F1Q36109051-BDE2BE93-2E29-449F-A29E-98239379EF52Q36172500-59E8F3B2-AAC7-4CDB-97B8-B2C4F933F532Q36322437-9DEF9042-6050-45D2-82C6-E8645A8F65B3Q36364100-76C47641-0473-46C0-9AEF-0CA1E74A3646Q36672181-CC6FAA02-F145-4993-8677-05B08100CDA4Q36703038-CC2BBB80-DDCA-498D-A555-C8C63007A5C6Q36747567-45684F21-5523-4364-8041-9FD4879FA501Q36785949-93E9ABA6-2600-45CB-9C0A-B41AEC83C19EQ36788428-7313DD53-9344-4889-84A5-09C61CA20F8AQ36849595-331ADEE4-5876-4289-A56C-A1BE5E8260A0Q36856930-EBE2D200-2D8A-4C70-89FD-74997C527F55Q36870777-A1037A27-5D93-4763-AA0C-7B5B61A7E7BDQ36933000-D03EC220-9761-48AA-A782-296C02F8EE57Q37115801-370BA87B-7913-4C57-98BA-3E29E05C7211Q37463223-D4EED13E-5785-4653-A08F-9352FD497ADEQ37500666-F942D2D5-0402-4561-BC7C-A26D706B8329Q37544379-AF084012-C3C0-4BB5-A97E-57A79FDE92DEQ37554055-6A2425C1-D5D5-4503-8215-0CA2AA250A63Q37608276-0DA80E97-FF45-48A5-A659-F7A919A272EA
P2860
Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Candida albicans and Candida g ...... d echinocandin susceptibility.
@en
type
label
Candida albicans and Candida g ...... d echinocandin susceptibility.
@en
prefLabel
Candida albicans and Candida g ...... d echinocandin susceptibility.
@en
P2093
P2860
P356
P1476
Candida albicans and Candida g ...... d echinocandin susceptibility.
@en
P2093
Michael Pfaller
Santosh Katiyar
Thomas Edlind
P2860
P304
P356
10.1128/AAC.00349-06
P407
P577
2006-08-01T00:00:00Z